# Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT02992522** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Christian** · enrollment: 22 (actual)

## Conditions studied

- B-Cell Lymphoma, Unspecified
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Recurrent Burkitt Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory Burkitt Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Transformed Recurrent Non-Hodgkin Lymphoma
- B-Cell

## Interventions

- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02992522
- **Lead sponsor:** Beth Christian
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-21
- **Primary completion:** 2026-08-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992522, "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02992522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*